ArticleOpen medicine (Warsaw, Poland)2025
Molecular hydrogen-rhodiola as an adjuvant therapy for ischemic stroke in internal carotid artery occlusion: A case report.
Article in Open medicine (Warsaw, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Acute ischemic stroke caused by internal carotid artery (ICA) occlusion carries high risks of disability and death. While treatments such as thrombolysis, mechanical thrombectomy, and revascularization offer benefits, many patients experience limited recovery. Molecular hydrogen, with its antioxidant and anti-inflammatory properties, shows promise as a neuroprotective agent. This case report explores the adjunctive use of molecular hydrogen-rhodiola therapy in a patient with ICA occlusion, with a focus on immune modulation and clinical outcomes. Case presentation: A 68-year-old male with a history of paroxysmal atrial fibrillation presented with left-sided hemiplegia and was diagnosed with right ICA occlusion (NIH Stroke Scale: 12; modified Rankin Scale: 5). Endovascular thrombectomy was attempted but unsuccessful (modified Thrombolysis in Cerebral Infarction score = 0). The patient subsequently underwent superficial temporal artery to middle cerebral artery bypass surgery. Postoperatively, he was initiated on daily molecular hydrogen-rhodiola capsule therapy. Serial immunological assessments demonstrated a progressive increase in type 1 regulatory T (Tr1) cells and regulatory B cells, along with enhanced T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) expression on cytotoxic T (Tc) cells. Clinically, the patient exhibited marked neurological recovery, with motor strength improving from Medical Research Council grade 1 to grade 5 in the affected limbs over six months. Notably, steroid therapy was discontinued without relapse, and no adverse events were observed. Conclusion: This case highlights the potential of molecular hydrogen-rhodiola therapy as a safe and effective adjunctive treatment for ischemic stroke due to ICA occlusion. Notable improvements in immune modulation and motor function support its possible role in neurovascular recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.